{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T17:43:46Z","timestamp":1740159826616,"version":"3.37.3"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T00:00:00Z","timestamp":1628726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T00:00:00Z","timestamp":1628726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s13318-021-00701-4","type":"journal-article","created":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T12:05:02Z","timestamp":1628769902000},"page":"685-694","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effects of Repeated Oral Administration of Esaxerenone on the Pharmacokinetics of Midazolam in Healthy Japanese Males"],"prefix":"10.1007","volume":"46","author":[{"given":"Kaoru","family":"Toyama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidetoshi","family":"Furuie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kana","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Ishizuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuyuki","family":"Okuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takako","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manabu","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Igawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Ishizuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,12]]},"reference":[{"key":"701_CR1","first-page":"866","volume":"107","author":"RE Schmieder","year":"2010","unstructured":"Schmieder RE. End organ damage in hypertension. Dtsch Arztebl Int. 2010;107:866\u201373.","journal-title":"Dtsch Arztebl Int"},{"key":"701_CR2","doi-asserted-by":"crossref","unstructured":"Perez MI, Musini VM. Pharmacological interventions for hypertensive emergencies: A Cochrane systematic review. J Hum Hypertens. 2008;22:596\u2013607.","DOI":"10.1038\/jhh.2008.25"},{"key":"701_CR3","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1038\/s41440-019-0284-9","volume":"42","author":"S Umemura","year":"2019","unstructured":"Umemura S, Arima H, Arima S, et al. The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2019). Hypertens Res. 2019;42:1235\u2013481.","journal-title":"Hypertens Res"},{"key":"701_CR4","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1161\/01.HYP.0000107251.49515.c2","volume":"42","author":"AV Chobanian","year":"2003","unstructured":"Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42:1206\u201352.","journal-title":"Hypertension"},{"key":"701_CR5","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1111\/j.1524-6175.2006.05504.x","volume":"8","author":"MA Tedesco","year":"2006","unstructured":"Tedesco MA, Natale F, Calabro R. Effects of monotherapy and combination therapy on blood pressure control and target organ damage: a randomized prospective intervention study in a large population of hypertensive patients. J Clin Hypertens (Greenwich). 2006;8:634\u201341.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"701_CR6","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1291\/hypres.25.57","volume":"25","author":"A Hozawa","year":"2002","unstructured":"Hozawa A, Ohkubo T, Kikuya M, et al. Blood pressure control assessed by home, ambulatory and conventional blood pressure measurements in the Japanese general population: the Ohasama study. Hypertens Res. 2002;25:57\u201363.","journal-title":"Hypertens Res"},{"key":"701_CR7","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.amjmed.2016.01.039","volume":"129","author":"M Epstein","year":"2016","unstructured":"Epstein M, Duprez DA. Resistant hypertension and the pivotal role for mineralocorticoid receptor antagonists: a clinical update 2016. Am J Med. 2016;129:661\u20136.","journal-title":"Am J Med"},{"key":"701_CR8","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/jhh.2015.119","volume":"30","author":"S Takahashi","year":"2016","unstructured":"Takahashi S, Katada J, Daida H, Kitamura F, Yokoyama K. Effects of mineralocorticoid receptor antagonists in patients with hypertension and diabetes mellitus: a systematic review and meta-analysis. J Hum Hypertens. 2016;30:534\u201342.","journal-title":"J Hum Hypertens"},{"key":"701_CR9","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s11906-016-0643-8","volume":"18","author":"H Narayan","year":"2016","unstructured":"Narayan H, Webb DJ. New evidence supporting the use of mineralocorticoid receptor blockers in drug-resistant hypertension. Curr Hypertens Rep. 2016;18:34.","journal-title":"Curr Hypertens Rep"},{"key":"701_CR10","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ijcard.2015.05.127","volume":"200","author":"M Lainscak","year":"2015","unstructured":"Lainscak M, Pelliccia F, Rosano G, et al. Safety profile of mineralocorticoid receptor antagonists: spironolactone and eplerenone. Int J Cardiol. 2015;200:25\u20139.","journal-title":"Int J Cardiol"},{"key":"701_CR11","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s40265-019-01073-5","volume":"79","author":"S Duggan","year":"2019","unstructured":"Duggan S. Esaxerenone: First global approval. Drugs. 2019;79:477\u201381.","journal-title":"Drugs"},{"key":"701_CR12","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.ejphar.2015.11.028","volume":"769","author":"K Arai","year":"2015","unstructured":"Arai K, Tsuruoka H, Homma T. CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats. Eur J Pharmacol. 2015;769:266\u201373.","journal-title":"Eur J Pharmacol"},{"key":"701_CR13","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1124\/jpet.116.234765","volume":"358","author":"K Arai","year":"2016","unstructured":"Arai K, Morikawa Y, Ubukata N, Tsuruoka H, Homma T. CS-3150, a novel nonsteroidal mineralocorticoid receptor antagonist, shows preventive and therapeutic effects on renal injury in deoxycorticosterone acetate\/salt-induced hypertensive rats. J Pharmacol Exp Ther. 2016;358:548\u201357.","journal-title":"J Pharmacol Exp Ther"},{"key":"701_CR14","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/s41440-018-0187-1","volume":"42","author":"L Li","year":"2019","unstructured":"Li L, Guan Y, Kobori H, et al. Effects of the novel nonsteroidal mineralocorticoid receptor blocker, esaxerenone (CS-3150), on blood pressure and urinary angiotensinogen in low-renin Dahl salt-sensitive hypertensive rats. Hypertens Res. 2019;42:769\u201378.","journal-title":"Hypertens Res"},{"key":"701_CR15","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1038\/s41440-019-0211-0","volume":"42","author":"AS Bhuiyan","year":"2019","unstructured":"Bhuiyan AS, Rafiq K, Kobara H, Masaki T, Nakano D, Nishiyama A. Effect of a novel nonsteroidal selective mineralocorticoid receptor antagonist, esaxerenone (CS-3150), on blood pressure and renal injury in high salt-treated type 2 diabetic mice. Hypertens Res. 2019;42:892\u2013902.","journal-title":"Hypertens Res"},{"key":"701_CR16","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1111\/bcp.13616","volume":"84","author":"M Kato","year":"2018","unstructured":"Kato M, Furuie H, Shimizu T, Miyazaki A, Kobayashi F, Ishizuka H. Single- and multiple-dose escalation study to assess pharmacokinetics, pharmacodynamics and safety of oral esaxerenone in healthy Japanese subjects. Br J Clin Pharmacol. 2018;84:1821\u20139.","journal-title":"Br J Clin Pharmacol"},{"key":"701_CR17","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1161\/HYPERTENSIONAHA.119.13569","volume":"75","author":"S Ito","year":"2020","unstructured":"Ito S, Ito H, Rakugi H, Okuda Y, Yoshimura M, Yamakawa S. A double-blind phase III study of esaxerenone (CS-3150) compared to eplerenone in patients with essential hypertension (ESAX-HTN study). Hypertension. 2020;75:51\u20138.","journal-title":"Hypertension"},{"key":"701_CR18","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s002280050706","volume":"55","author":"M Katoh","year":"2000","unstructured":"Katoh M, Nakajima M, Shimada N, Yamazaki H, Yokoi T. Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol. 2000;55:843\u201352.","journal-title":"Eur J Clin Pharmacol"},{"key":"701_CR19","first-page":"125","volume":"28","author":"B Ma","year":"2000","unstructured":"Ma B, Prueksaritanont T, Lin JH. Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000;28:125\u201330.","journal-title":"Drug Metab Dispos"},{"key":"701_CR20","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1016\/j.jacc.2008.07.055","volume":"52","author":"JM Siller-Matula","year":"2008","unstructured":"Siller-Matula JM, Lang I, Christ G, Jilma B. Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. J Am Coll Cardiol. 2008;52:1557\u201363.","journal-title":"J Am Coll Cardiol"},{"key":"701_CR21","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/pds.1480","volume":"17","author":"M Yoshida","year":"2008","unstructured":"Yoshida M, Matsumoto T, Suzuki T, Kitamura S, Mayama T. Effect of concomitant treatment with a CYP3A4 inhibitor and a calcium channel blocker. Pharmacoepidemiol Drug Saf. 2008;17:70\u20135.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"701_CR22","doi-asserted-by":"publisher","first-page":"806","DOI":"10.2174\/1381612820666141024151119","volume":"21","author":"A Zisaki","year":"2015","unstructured":"Zisaki A, Miskovic L, Hatzimanikatis V. Antihypertensive drugs metabolism: an update to pharmacokinetic profiles and computational approaches. Curr Pharm Des. 2015;21:806\u201322.","journal-title":"Curr Pharm Des"},{"key":"701_CR23","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1124\/dmd.120.090928","volume":"48","author":"M Yamada","year":"2020","unstructured":"Yamada M, Ishizuka T, Inoue SI, Rozehnal V, Fischer T, Sugiyama D. Drug\u2013drug interaction risk assessment of esaxerenone as a perpetrator by in vitro studies and static and physiologically based pharmacokinetic models. Drug Metab Dispos. 2020;48:769\u201377.","journal-title":"Drug Metab Dispos"},{"key":"701_CR24","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1124\/jpet.104.082826","volume":"314","author":"A Galetin","year":"2005","unstructured":"Galetin A, Ito K, Hallifax D, Houston JB. CYP3A4 substrate selection and substitution in the prediction of potential drug\u2013drug interactions. J Pharmacol Exp Ther. 2005;314:180\u201390.","journal-title":"J Pharmacol Exp Ther"},{"key":"701_CR25","unstructured":"US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Clinical drug interaction studies\u2014Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions Guidance for Industry. Guidance document, 2017. https:\/\/www.fda.gov\/media\/134581\/download. Accessed 23 Jun 2021."},{"key":"701_CR26","unstructured":"Ministry of Health, Labour and Welfare, Tokyo, Japan; 2017. Guideline on drug interactions for drug development and information provision (final draft), PFSB\/ELD Notice. https:\/\/www.pmda.go.jp\/files\/000225191.pdf. Accessed 23 Jun 2021."},{"key":"701_CR27","first-page":"549","volume":"271","author":"KE Thummel","year":"1994","unstructured":"Thummel KE, Shen DD, Podoll TD, et al. Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. J Pharmacol Exp Ther. 1994;271:549\u201356.","journal-title":"J Pharmacol Exp Ther"},{"key":"701_CR28","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/j.clinthera.2017.04.009","volume":"39","author":"SK Paulson","year":"2017","unstructured":"Paulson SK, Wood-Horrall RN, Hoover R, Quintas M, Lawrence LE, Cammarata SK. The pharmacokinetics of the CYP3A substrate midazolam after steady-state dosing of delafloxacin. Clin Ther. 2017;39:1182\u201390.","journal-title":"Clin Ther"},{"key":"701_CR29","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1177\/0091270003261333","volume":"44","author":"H Zhou","year":"2004","unstructured":"Zhou H, Tong Z, McLeod JF. \u201cCocktail\u201d approaches and strategies in drug development: valuable tool or flawed science? J Clin Pharmacol. 2004;44:120\u201334.","journal-title":"J Clin Pharmacol"},{"key":"701_CR30","doi-asserted-by":"publisher","first-page":"e00033","DOI":"10.1002\/prp2.33","volume":"2","author":"G Jang","year":"2014","unstructured":"Jang G, Kaufman A, Lee E, et al. A clinical therapeutic protein drug\u2013drug interaction study: coadministration of denosumab and midazolam in postmenopausal women with osteoporosis. Pharmacol Res Perspect. 2014;2:e00033.","journal-title":"Pharmacol Res Perspect"},{"key":"701_CR31","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1002\/jcph.7","volume":"53","author":"S Urva","year":"2013","unstructured":"Urva S, Bouillaud E, Delaney R, Jappe A, Cheung W. A phase I study evaluating the effect of everolimus on the pharmacokinetics of midazolam in healthy subjects. J Clin Pharmacol. 2013;53:444\u201350.","journal-title":"J Clin Pharmacol"},{"key":"701_CR32","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/S1367-5931(00)00228-3","volume":"5","author":"PR Chaturvedi","year":"2001","unstructured":"Chaturvedi PR, Decker CJ, Odinecs A. Prediction of pharmacokinetic properties using experimental approaches during early drug discovery. Curr Opin Chem Biol. 2001;5:452\u201363.","journal-title":"Curr Opin Chem Biol"},{"key":"701_CR33","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0009-9236(96)90177-0","volume":"59","author":"KE Thummel","year":"1996","unstructured":"Thummel KE, O\u2019Shea D, Paine MF, et al. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther. 1996;59:491\u2013502.","journal-title":"Clin Pharmacol Ther"},{"key":"701_CR34","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S0009-9236(98)90146-1","volume":"64","author":"JC Gorski","year":"1998","unstructured":"Gorski JC, Jones DR, Haehner-Daniels BD, Hamman MA, O\u2019Mara EM Jr, Hall SD. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin Pharmacol Ther. 1998;64:133\u201343.","journal-title":"Clin Pharmacol Ther"},{"key":"701_CR35","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1111\/j.1365-2125.2010.03624.x","volume":"69","author":"F Qiu","year":"2010","unstructured":"Qiu F, Wang G, Zhang R, Sun J, Jiang J, Ma Y. Effect of danshen extract on the activity of CYP3A4 in healthy volunteers. Br J Clin Pharmacol. 2010;69:656\u201362.","journal-title":"Br J Clin Pharmacol"},{"key":"701_CR36","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0169-409X(97)00039-2","volume":"27","author":"DD Shen","year":"1997","unstructured":"Shen DD, Kunze KL, Thummel KE. Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction. Adv Drug Deliv Rev. 1997;27:99\u2013127.","journal-title":"Adv Drug Deliv Rev"},{"key":"701_CR37","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s40360-020-00423-4","volume":"21","author":"Y Kirigaya","year":"2020","unstructured":"Kirigaya Y, Shiramoto M, Ishizuka T, et al. Pharmacokinetic interactions of esaxerenone with amlodipine and digoxin in healthy Japanese subjects. BMC Pharmacol Toxicol. 2020;21:55.","journal-title":"BMC Pharmacol Toxicol"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-021-00701-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-021-00701-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-021-00701-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T08:27:13Z","timestamp":1630052833000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-021-00701-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,12]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["701"],"URL":"https:\/\/doi.org\/10.1007\/s13318-021-00701-4","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"type":"print","value":"0378-7966"},{"type":"electronic","value":"2107-0180"}],"subject":[],"published":{"date-parts":[[2021,8,12]]},"assertion":[{"value":"24 June 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Daiichi Sankyo Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"KT, KK, TI, YO, TS, MK, YI, YN, and HI are employees of Daiichi Sankyo Co., Ltd. KK, TI, TS, YI, and HI own stocks in the company. HF has received research funding for this study from Daiichi Sankyo Co., Ltd.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The study was conducted after review and approval by the institutional review board of Osaka Pharmacology Clinical Research Hospital, Osaka, Japan (control number of the study site 930PC). The study was conducted in accordance with Good Clinical Practice and ethical principles of the Declaration of Helsinki and the Pharmaceuticals, Medical Devices, and Other\nTherapeutic Products Act.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All subjects provided written informed consent to be included in the study (JapicCTI No. 152832).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"KK, TI, and YO performed all statistical analyses. KT drafted the manuscript. HF conducted the study and collected the data. All authors contributed to the design and implementation of the research and provided critical feedback on the manuscript. All authors approved the final manuscript before submission.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Contributors"}},{"value":"All de-identified patient data relevant to this study are included in this article. Additional data and supporting documents pertaining to this study are provided upon reasonable request made via this web address () in accordance with the data sharing policy of Daiichi Sankyo Co., Ltd.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Sharing Statement"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}